Awan Anum Munir, Farid Arshad, Shah Shefaat Ullah, Khan Dildar, Ur Rehman Fiza, Dar Muhammad Junaid, Iftikhar Tayyaba, Ghazanfar Shakira, Galanakis Charis M, Alamri Abdulhakeem S, Asdaq Syed Mohammed Basheeruddin, Shah Kifayat Ullah
Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan 29050, Pakistan.
Pharmaceutics. 2022 Jun 18;14(6):1300. doi: 10.3390/pharmaceutics14061300.
The aim of this study was to improve the saturation solubility, dissolution profile and oral bioavailability of amiodarone hydrochloride (AMH), a highly lipophilic drug. Stabilizer (Pluronic F-127)-coated AMH nanocrystals (AMH-NCs) were developed by a combination of antisolvent precipitation and homogenization techniques. The optimized formulation comprised pluronic F-127 and AMH at the concentration of 4% and 2% w/v, respectively. The particle size (PS), zeta potential (ZP) and polydispersity index (PDI) of the optimized formulation was found to be 221 ± 1.2 nm, 35.3 mV and 0.333, respectively. The optimized formulation exhibited a rough surface morphology with particles in colloidal dimensions and a significant reduction in crystallinity of the drug. AMH-NCs showed a marked increase in the saturation solubility as well as rapid dissolution rate when compared with the AMH and marketed product. The stability study displayed that the formulation was stable for 3 months, with no significant change in the PS, ZP and PDI. The in vivo pharmacokinetic study demonstrated the ability of AMH-NCs to significantly (p < 0.05) improve the oral bioavailability (2.1-fold) of AMH in comparison with AMH solution, indicating that the production of AMH-NCs using a combination of antisolvent precipitation and homogenization techniques could enhance the bioavailability of the drug.
本研究的目的是提高盐酸胺碘酮(AMH)的饱和溶解度、溶出度和口服生物利用度,盐酸胺碘酮是一种高度亲脂性药物。通过反溶剂沉淀和均质技术相结合的方法制备了稳定剂(泊洛沙姆F-127)包衣的AMH纳米晶体(AMH-NCs)。优化后的制剂分别包含浓度为4%和2%(w/v)的泊洛沙姆F-127和AMH。优化制剂的粒径(PS)、ζ电位(ZP)和多分散指数(PDI)分别为221±1.2nm、35.3mV和0.333。优化后的制剂呈现出粗糙的表面形态,颗粒呈胶体尺寸,药物的结晶度显著降低。与AMH和市售产品相比,AMH-NCs的饱和溶解度显著增加,溶出速率加快。稳定性研究表明,该制剂在3个月内稳定,PS、ZP和PDI无显著变化。体内药代动力学研究表明,与AMH溶液相比,AMH-NCs能够显著(p<0.05)提高AMH的口服生物利用度(2.1倍),这表明采用反溶剂沉淀和均质技术相结合制备AMH-NCs可以提高药物的生物利用度。